If you are passionate about our mission to develop innovative therapies that target some of the most difficult-to-treat human diseases, consider joining our expanding team of talented professionals. View our #OpenPositions here: https://lnkd.in/gekwX8wy
ImmunityBio, Inc.
Biotechnology Research
San Diego, CA 18,527 followers
Outsmart Your Disease™
About us
ImmunityBio, Inc. (formerly NantKwest, Inc.) is developing cell and immunotherapy products that are designed to help strengthen each patient’s natural immune system, potentially enabling it to outsmart the disease and eliminate cancerous or infected cells. The activation of the innate immune system is key to the development of immunological memory. Over the last two decades, our founder and Executive Chairman Dr. Patrick Soon-Shiong has investigated mechanisms to activate the immune system to attack tumors that can otherwise evade and escape the body’s defense mechanisms. After inventing the world’s first protein nanoparticle drug, Abraxane, Dr. Soon-Shiong turned his focus to the next generation of immunotherapies. ImmunityBio was founded in 2014 to create innovative immunotherapies that address serious unmet needs in oncology and infectious diseases. "At ImmunityBio, we envision a day when we no longer fear cancer but are able to conquer it, thanks to the biological wonder that is the human immune system. Our scientists are working to develop remarkable new therapies that harness that inherent power by amplifying both branches of the immune system, attacking cancerous or infected cells today while building immunological memory for tomorrow. The goal: to reprogram the patient’s immune system and treat the host rather than just the disease." -Dr. Patrick Soon-Shiong, Executive Chairman
- Website
-
https://www.ImmunityBio.com
External link for ImmunityBio, Inc.
- Industry
- Biotechnology Research
- Company size
- 501-1,000 employees
- Headquarters
- San Diego, CA
- Type
- Public Company
- Specialties
- Immunotherapy, Cancer, Infectious Diseases, Natural Killer, T Cell, Vaccines, Oncology, Vaccine, Fusion Proteins, Clinical Trials, Manufacturing, COVID-19, Yeast, and Cell Therapy
Locations
Employees at ImmunityBio, Inc.
Updates
-
In the U.S., approximately 12,000 people are diagnosed with #Glioblastoma annually. On Glioblastoma Awareness Day, ImmunityBio reaffirms our commitment to advancing research for better patient outcomes. Learn more: https://lnkd.in/gm8a_Bfh
-
ImmunityBio founder Dr. Patrick Soon-Shiong shared his remarkable journey on the Healthcare Unfiltered podcast. From apartheid-era South Africa to global success, he overcame adversity, pioneered cancer treatments, and continues to make a difference. Listen: https://lnkd.in/gasdpHXi
-
At ImmunityBio we are revolutionizing cancer and infectious disease treatments with a powerful new approach. Our therapies are designed to do more than today's treatments by boosting the body's own immune response for long-term protection. #NextGenImmunotherapy #ImmunityBio
-
Exciting news! ImmunityBio is partnering with the National Cancer Institute (NCI) on a groundbreaking U.S. cancer vaccine study targeting Lynch syndrome. Learn more at: https://lnkd.in/gz9jKTG and https://lnkd.in/gnkTPQsW.
-
Can immunotherapy treat cancer in dogs? The New York Times interviewed ImmunityBio's chief science officer for cellular products (and certified dog lover), Dr. Hans Klingemann to learn more about his personal research into this question. https://lnkd.in/gjQcjkmB
-
Firefighters face high risks every day — and they’re also at a higher risk of developing bladder cancer due to exposure to carcinogens on the job. We salute these everyday heroes — and those who advocate for more research into bladder cancer. Learn more at BCAN: https://lnkd.in/dS8TQUU
-
In case you missed it, earlier today we announced the first NMIBC patients have been treated with commercially available doses of ANKTIVA, less than two months after we received FDA approval for this exciting new therapy. Learn more: https://lnkd.in/gGEeHu7w
ImmunityBio Announces Insurance Coverage of ANKTIVA® Across Multiple States with First Commercial Doses Administered Just Weeks After FDA Approval—Opening New Era for Immunotherapy Beyond Checkpoint Inhibitors - ImmunityBio
https://immunitybio.com
-
We met with Robin Beth Dubin of http://Aliveandkickn.org, they're doing great work for Lynch syndrome "previvors." We're honored to partner with National Cancer Institute (NCI) on one of two U.S. cancer vaccine studies focused on Lynch syndrome. Learn more at http://AliveandKickin.org and http://Livingwithlynch.org.
AliveAndKickn
aliveandkickn.org